Patient-reported distress and clinical outcomes with immuno-oncology agents in metastatic non-small cell lung cancer (mNSCLC): a real-world retrospective cohort …
Objectives There are limited real-world data about patient-reported outcomes with
immunotherapies (IO) in metastatic non-small cell lung cancer (mNSCLC). We describe …
immunotherapies (IO) in metastatic non-small cell lung cancer (mNSCLC). We describe …
Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type
Aims This study described treatment patterns, healthcare resource utilization (HRU) and
costs among advanced or metastatic non-small cell lung cancer (a/mNSCLC) patients with …
costs among advanced or metastatic non-small cell lung cancer (a/mNSCLC) patients with …
[HTML][HTML] Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the …
J Vanderpoel, B Emond, I Ghelerter, K Milbers… - PharmacoEconomics …, 2023 - Springer
Abstract Background An estimated 10–15% of non-small cell lung cancer (NSCLC) cases
present with epidermal growth factor receptor mutation (EGFRm). While EGFR tyrosine …
present with epidermal growth factor receptor mutation (EGFRm). While EGFR tyrosine …
Treatment patterns and healthcare resource utilization and payments in patients with lung cancer in the Texas Medicaid program
X Ma - 2023 - repositories.lib.utexas.edu
The economic burden associated with the treatment of lung cancer is substantial. With the
introduction of targeted therapy and immunotherapy, treatment options for lung cancer …
introduction of targeted therapy and immunotherapy, treatment options for lung cancer …